The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

Solid Tumor Clinical Trial

— FINPROVE  

Official title:

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs to Determine the Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05159245
• Other study ID #: FINPROVE
• Status: Recruiting
• Phase: Phase 2
• Start date: December 10, 2021
• Est. completion date: November 25, 2026

Study information

• Verified date: September 2023
• Source: Helsinki University Central Hospital
• Contact: Tanja Juslin
• Phone: +358405597415
• Email: tanja.juslin[@]hus.fi
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective non-randomized national clinical phase 2 trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test.

Description:

This is a prospective non-randomized clinical trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test. The study also aims to facilitate patient access to approved targeted therapies that are contributed to the program by collaborating pharmaceutical companies and to perform next generation sequencing and further deeper analysis on tumor biopsies and/or liquid biopsies for biomarker analyses and resistance mechanisms. Eligible patients have an advanced cancer for which standard treatment options no longer exist and acceptable performance status and organ function. A tumour DNA, RNA or protein expression analysis is required and the results must identify at least one potentially actionable molecular variant as defined in the protocol. Molecular profiling will be utilized to determine an appropriate drug(s) from among those available in the protocol. Drug selection will be guided by a list of potential profiles, the molecular tumor board and databases of identified targets for review and approval of the recommended treatment. The protocol-specified treatment will be administered to the patient once any drug- and disease specific eligibility criteria and overall study criteria are met. Data for standard efficacy outcomes including tumor response, progression-free and overall survival as well as duration of treatment will be collected for all patients receiving treatment within the trial. In addition, treatment related toxicity will be collected according to CTCAE 5.0.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 250
• Est. completion date: November 25, 2026
• Est. primary completion date: November 25, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

1. Adult (age >18 years) patient with a histologically-confirmed locally advanced or metastatic cancer who is no longer benefitting from standard anti-cancer treatment or for whom no such treatment is available or indicated.

2. ECOG performance status 0-2

3. Patients must have acceptable organ function as defined below. However, specific inclusion/exclusion criteria specified in the drug-specific study manual will take precedence:

1. Absolute neutrophil count = 1.5 x 109/l

2. Hemoglobin > 8.0 mmol/l

3. Platelets > 75 x 109/l

4. Total bilirubin < 1.5 x ULN

5. AST and ALT < 3 x institutional ULN (or < 5 x ULN in patients with known hepatic metastases)

6. Serum creatinine = 1.5 × ULN or calculated or measured creatinine clearance = 40 mL/min/1.73 m2

4. Patients must have objectively evaluable or measurable disease (by physical or radiographic examination, according to RECIST v1.1, Lugano, IWG and ELN-AML, IMWG, RANO, GCIG, iRESIST or PCWG3.

5. Results must be available from a tumor molecular profiling. Eligible tests may include any of the following technologies: fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), comparative genomic hybridization (CGH), next generation sequencing (NGS) or immunohistochemistry (IHC). The test may have been performed on the primary tumor or a metastatic lesion, in a diagnostic laboratory or within the context of another commercial platform (eg Foundation Medicine), and must reveal a potentially actionable variant.

6. Patients must have a tumor profile for which treatment with one of the EMA approved (or under revision for approval) targeted anti-cancer drugs included in this study has potential clinical benefit based on preclinical data or clinical information.

7. A new (obtained =6 months before inclusion after which no further anti-cancer therapy is allowed) fresh frozen and FFPE tumor biopsy specimen or liquid biopsy for extensive biomarker testing is mandatory before the start of treatment with a targeted agent included in the protocol.

8. Ability to understand and the willingness to sign a written informed consent document and comply to the protocol.

9. For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.

10. Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Male patients should avoid impregnating a female partner. Male patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, or completely abstain from sexual intercourse.

Exclusion Criteria:

1. Ongoing toxicity > grade 2, other than alopecia or > grade 1 neuropathy.

2. Patient is receiving any other anti-cancer therapy (cytotoxic, biologic, radiation, or hormonal other than for replacement). Required wash out period prior to starting study treatment is at least two weeks. An exception is made for:

1. Patients suffering from CRPC are allowed to continue androgen deprivation therapy.

2. Medications that are prescribed for supportive care but may potentially have an anti-cancer effect (e.g., megestrol acetate, bisphosphonates). These medications must have been started = 1 week prior to enrollment on this study.

3. Patient is pregnant or nursing.

4. Patients with known active progressive brain metastases. Patients with previously treated brain metastases are eligible, provided that the patient is clinically stable and off steroids for at least 4 weeks prior to study initiation.

5. Patients with clinically significant preexisting cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure are not eligible.

6. Patients with known left ventricular ejection fraction (LVEF) < 45% are not eligible

7. Patients with stroke (including TIA) or acute myocardial infarction within 3 months before the first dose of study treatment are not eligible

8. Patients with any other clinically significant medical condition which, in the opinion of the treating physician, makes it undesirable for the patient to participate in the study or which could jeopardize compliance with study requirements including, but not limited to: ongoing or active infection, significant uncontrolled hypertension, or severe psychiatric illness/social situations.

For each drug included in this protocol, specific inclusion and exclusion criteria (based on the Package Insert or manufacturers recommendations) may also apply. These can be found in the supplemental information for each agent included in the drug-specific study manuals. Drug-specific inclusion and exclusion criteria will take precedence over the inclusion/exclusion criteria listed above.

Related Conditions & MeSH terms

• Advanced Cancer
• Haematological Malignancy
• Hematologic Neoplasms
• Solid Tumor

Intervention

Drug:
• Alectinib
ALK
• Cobimetinib
MEK1, MEK2
• Vismodegib
Hedgehog
• Trastuzumab+Pertuzumab
HER2
• Entrectinib
NTRK/ ROS1, ALK
• Atezolizumab
PD-L1
• Vemurafenib
BRAF V600
• Regorafenib
KIT/BRAF, RET
• Apalutamide
AR
• Abemaciclib
CDK4/6
• Selpercatinib
RET
• Dabrafenib
RAF
• Trametinib
MEK1, MEK2
• Dabrafenib+Trametinib
RAF, MEK1, MEK2
• Pralsetinib
RET

Locations

Country	Name	City	State
Finland	Helsinki University Hospital Comprehensive Cancer Center	Helsinki	Uusimaa
Finland	Kuopio University Hospital	Kuopio
Finland	Tampere University Hospital Department of Oncology	Tampere
Finland	Turku University Hospital Cancer Centre	Turku	Varsinais-Suomi

Sponsors (1)

Lead Sponsor	Collaborator
Helsinki University Central Hospital

Country where clinical trial is conducted

Finland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disease control rate	Disease control rate at 16 weeks after treatment initiation (defined as patients by CR, PR, SD)	16 weeks
Secondary	Duration of treatment	Time on drug	5 years
Secondary	Adverse Events	Treatment-related grade =3 and serious adverse events	5 years
Secondary	Overall response	Best overall response (defined as patients by CR, PR, SD)	5 years
Secondary	PFS	Progression free survival	5 years
Secondary	OS	Overall survival	5 years